[144] UroGen Pharma Ltd. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for UroGen Pharma Ltd. (URGN) reports a proposed sale of 871 ordinary shares through Oppenheimer & Co. on 09/08/2025 with an aggregate market value of $16,444.48. The shares were acquired as RSUs on 09/07/2023 totaling 3,333 units for this grant, with payment recorded on the acquisition date. The filing also discloses two prior ordinary-share sales by the same seller in the past three months: 5,149 shares on 07/28/2025 for $98,551.86 and 5,162 shares on 06/09/2025 for $38,043.94. The filer affirms no undisclosed material adverse information about the issuer.

Positive

• Compliance disclosure: The filer provides required Rule 144 details including acquisition date, nature (RSU), broker, and sale date.
• Transparency on recent sales: Two prior sales in the past three months are fully reported with dates and gross proceeds.

Negative

• Insider selling activity: Recent sales of 10,311 shares in the past three months generated total gross proceeds of $136,595.80.
• Ongoing disposition: Proposed sale of 871 shares (value $16,444.48) indicates continued insider share reductions.

Insights

Securities Analyst

TL;DR: Insider sale disclosure: small proposed sale plus recent larger dispositions; routine compliance rather than clear signal of material company change.

The filing documents a proposed sale of 871 ordinary shares valued at $16,444.48, acquired as RSUs on 09/07/2023. Recent completed sales in the past three months total 10,311 shares with combined gross proceeds of $136,595.80. Against an outstanding share count of 46,264,132 reported for the class, the disclosed amounts represent a de minimis proportion of total outstanding shares, suggesting limited direct market impact. The filing is primarily a Rule 144 compliance notice and includes the required attestation regarding undisclosed material information.

Corporate Governance Expert

TL;DR: The disclosure meets Rule 144 reporting requirements; recent insider sales are documented but show no stated material nonpublic information.

The filer provides acquisition details (RSU grant on 09/07/2023 for 3,333 shares) and sale logistics (broker, sale date 09/08/2025). Two prior sales in June and July 2025 are recorded with specific proceeds. The signature block includes the standard representation that no material adverse information is known and references potential 10b5-1 plan disclosure. From a governance perspective, the filing supplies the necessary transparency for insider transactions without additional commentary or governance actions disclosed.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary	Oppenheimer & Co. Inc. 85 Broad St. New York NY 10004	871	16444.48	46264132	09/08/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary	09/07/2023	RSU	Issuer			3333	09/07/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Schoenberg 9 HA'TA'ASIYA ST RA'ANANA L3 4365007	Ordinary	07/28/2025	5149	98551.86
Mark Schoenberg 9 HA'TA'ASIYA ST RA'ANANA L3 4365007	Ordinary	06/09/2025	5162	38043.94

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for UroGen Pharma (URGN) report?

It reports a proposed sale of 871 ordinary shares through Oppenheimer on 09/08/2025 valued at $16,444.48, with acquisition as RSUs on 09/07/2023.

Who is the seller named in the Form 144?

The seller is Mark Schoenberg, with recent sales listed at his address and prior transactions in June and July 2025.

How many shares were sold by the filer in the past three months?

10,311 shares were sold: 5,162 on 06/09/2025 and 5,149 on 07/28/2025, with combined gross proceeds of $136,595.80.

What were the purchase details for the securities being sold?

The securities were acquired as RSUs on 09/07/2023, totaling 3,333 units in that acquisition, with payment recorded on the same date.

Which broker is handling the proposed sale?

Oppenheimer & Co. Inc., 85 Broad St. New York, NY 10004 is listed as the broker for the proposed transaction.